Cargando…

Pregnancy Outcomes in Systemic Vasculitides

PURPOSE OF REVIEW: In recent years, improvements in the recognition of primary vasculitides and increased treatment options have led to greater survival rates and a better quality of life for patients. Therefore, pregnancy in women with vasculitis has become a more frequent consideration or event. L...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Carolyn, D’Souza, Rohan, Pagnoux, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448704/
https://www.ncbi.nlm.nih.gov/pubmed/32845412
http://dx.doi.org/10.1007/s11926-020-00940-5
_version_ 1783574530805989376
author Ross, Carolyn
D’Souza, Rohan
Pagnoux, Christian
author_facet Ross, Carolyn
D’Souza, Rohan
Pagnoux, Christian
author_sort Ross, Carolyn
collection PubMed
description PURPOSE OF REVIEW: In recent years, improvements in the recognition of primary vasculitides and increased treatment options have led to greater survival rates and a better quality of life for patients. Therefore, pregnancy in women with vasculitis has become a more frequent consideration or event. Literature on pregnancy outcomes in this population has grown and allowed us, in this article, to review the effects of pregnancy on disease activity, as well as maternal and fetal outcomes for each type of vasculitides. RECENT FINDINGS: Successful pregnancies in patients with vasculitides are possible, especially when conception is planned, and the disease is in remission. The risk of vasculitis flare is highly dependent on the type of vasculitis, but overall limited. The most frequent complication associated with large-vessel vasculitis (mainly Takayasu arteritis) is hypertension and preeclampsia. Preterm deliveries and intrauterine growth restriction occur more frequently with small- and medium-vessel vasculitis. SUMMARY: Pregnancies in patients with vasculitis should be considered high risk and followed by a multidisciplinary team with expertise in the field. Flares should be managed as in the non-pregnant population, while avoiding medications with unknown safety in pregnancy or known teratogens. Although commonly prescribed for the prevention of preeclampsia, there is limited evidence supporting the use of low-dose aspirin for pregnant women with vasculitis. Prospective registries or studies are needed, to better assess the value of aspirin, the place and long-term impact of new biologics and, to identify predictors of pregnancy outcomes other than disease status at conception.
format Online
Article
Text
id pubmed-7448704
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-74487042020-08-27 Pregnancy Outcomes in Systemic Vasculitides Ross, Carolyn D’Souza, Rohan Pagnoux, Christian Curr Rheumatol Rep Vasculitis (L Espinoza, Section Editor) PURPOSE OF REVIEW: In recent years, improvements in the recognition of primary vasculitides and increased treatment options have led to greater survival rates and a better quality of life for patients. Therefore, pregnancy in women with vasculitis has become a more frequent consideration or event. Literature on pregnancy outcomes in this population has grown and allowed us, in this article, to review the effects of pregnancy on disease activity, as well as maternal and fetal outcomes for each type of vasculitides. RECENT FINDINGS: Successful pregnancies in patients with vasculitides are possible, especially when conception is planned, and the disease is in remission. The risk of vasculitis flare is highly dependent on the type of vasculitis, but overall limited. The most frequent complication associated with large-vessel vasculitis (mainly Takayasu arteritis) is hypertension and preeclampsia. Preterm deliveries and intrauterine growth restriction occur more frequently with small- and medium-vessel vasculitis. SUMMARY: Pregnancies in patients with vasculitis should be considered high risk and followed by a multidisciplinary team with expertise in the field. Flares should be managed as in the non-pregnant population, while avoiding medications with unknown safety in pregnancy or known teratogens. Although commonly prescribed for the prevention of preeclampsia, there is limited evidence supporting the use of low-dose aspirin for pregnant women with vasculitis. Prospective registries or studies are needed, to better assess the value of aspirin, the place and long-term impact of new biologics and, to identify predictors of pregnancy outcomes other than disease status at conception. Springer US 2020-08-26 2020 /pmc/articles/PMC7448704/ /pubmed/32845412 http://dx.doi.org/10.1007/s11926-020-00940-5 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Vasculitis (L Espinoza, Section Editor)
Ross, Carolyn
D’Souza, Rohan
Pagnoux, Christian
Pregnancy Outcomes in Systemic Vasculitides
title Pregnancy Outcomes in Systemic Vasculitides
title_full Pregnancy Outcomes in Systemic Vasculitides
title_fullStr Pregnancy Outcomes in Systemic Vasculitides
title_full_unstemmed Pregnancy Outcomes in Systemic Vasculitides
title_short Pregnancy Outcomes in Systemic Vasculitides
title_sort pregnancy outcomes in systemic vasculitides
topic Vasculitis (L Espinoza, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448704/
https://www.ncbi.nlm.nih.gov/pubmed/32845412
http://dx.doi.org/10.1007/s11926-020-00940-5
work_keys_str_mv AT rosscarolyn pregnancyoutcomesinsystemicvasculitides
AT dsouzarohan pregnancyoutcomesinsystemicvasculitides
AT pagnouxchristian pregnancyoutcomesinsystemicvasculitides